Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus (Abstract)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus Case Reports; JAAD Case Rep 19 June 2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339115/ A rare subtype of epidermolysis bullosa, epidermolysis bullosa pruriginosa (EBP) is characterized by severely pruritic lichenified and hypertrophic prurigo-like nodules and plaques secondary to chronic itching. No standard first-line therapy currently exists. Reported is a case of […]

Ocular surface itch and pain: key differences and similarities between the two sensations (Abstract)

Ocular surface itch and pain: key differences and similarities between the two sensations Curr Opin Allergy Clin Immunol 25 July 2023 https://pubmed.ncbi.nlm.nih.gov/37490616/ Purpose of review: To review the pathophysiology and treatment of ocular itch and pain, encompassing nociceptive and neuropathic categories. Recent findings: Ocular itch and pain are sensations that arise from activation of ocular […]

The Utilization of Low Dose Naltrexone for Chronic Pain (Abstract)

The Utilization of Low Dose Naltrexone for Chronic Pain CNS Drugs 28 July 2023 https://pubmed.ncbi.nlm.nih.gov/37505425/ Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone […]

Low Dose Naltrexone’s Utility for Non-Cancer Centralized Pain Conditions… (Abstract)

Low Dose Naltrexone’s Utility for Non-Cancer Centralized Pain Conditions – A Scoping Review Pain Med 11 June 2023 https://pubmed.ncbi.nlm.nih.gov/37302106/ Background: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. One of the most likely contributors to centralized pain is changes in […]

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series (Abstract)

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series J Pain Res 14 June 2023 https://pubmed.ncbi.nlm.nih.gov/37337611/ Purpose: Low-dose naltrexone (LDN) has increased in popularity as a non-opioid medication that may decrease chronic pain symptoms. LDN is most commonly used to treat fibromyalgia, complex regional pain syndrome (CRPS), and painful diabetic neuropathy. […]

Opiate Antagonists for Chronic Pain… (Abstract)

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases Biomedicines 02 June 2023 https://pubmed.ncbi.nlm.nih.gov/37371715/ Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that […]

Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of … (Abstract)

Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of Human Adipose-Derived Mesenchymal Stem Cells Iran J Immunol 31 May 2023 https://pubmed.ncbi.nlm.nih.gov/37151015/ Background: Low-dose naltrexone (LDN) is involved in the treatment of inflammatory and immune system diseases and can affect immune cells. Mesenchymal stem cells (MSCs) are known for their immunomodulatory effects and the potential for […]

Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery … (Abstract)

Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice Neurochem Res 11 May 2023 https://pubmed.ncbi.nlm.nih.gov/37166576/ Diabetic patients experience significant mortality and poor recovery following ischemic stroke. Our clinical and basic science studies demonstrate an overall immune suppression in the periphery of diabetic stroke patients, as well as […]

A systematic literature review on the clinical efficacy of low dose naltrexone … (Abstract)

A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia Heliyon 19 April 2023 https://pubmed.ncbi.nlm.nih.gov/37206027/ Background: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising […]

Low-Dose Naltrexone in Rheumatological Diseases (Abstract)

Low-Dose Naltrexone in Rheumatological Diseases Mediterr J Rheumatol 31 March 2023 https://pubmed.ncbi.nlm.nih.gov/37223594/ Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders. Aim: To review the use of LDN in rheumatic diseases: systemic […]